Objective To determine the median effective dose （ED50） and 95% effective dose （ED95） of oliceridine combined with propofol （plasma target-controlled concentration at 3 μg/mL） for painless gastrointestinal endoscopy. Methods A total of 27 patients scheduled for painless gastrointestinal endoscopy from July to December 2024 were enrolled. All patients received propofol via target-controlled infusion （TCI） at a plasma concentration of 3 μg/mL. The modified Dixon's up-and-down sequential method was used to determine the oliceridine dose （initial dose 1 mg,step size 0.1 mg）. The dose for each subsequent patient was adjusted based on the response of the previous patient （positive response： coughing, retching, or purposeful movement during endoscopy）, with an increase after a positive response and a decrease after a negative response. The study was terminated after 7 response crossovers. Probit regression analysis was used to calculate the ED50, ED95, and their 95% confidence intervals （CIs） for oliceridine. Results The ED50 of oliceridine combined with propofol （TCI 3 μg/mL） for gastrointestinal endoscopy was 0.829 mg （95%CI 0.509-1.053 mg）, and the ED95 was 1.176 mg （95%CI 0.997-4.936 mg）. Conclusion When oliceridine is combined with propofol （TCI 3 μg/mL） for gastrointestinal endoscopy, the ED95 of oliceridine to suppress the insertion response is 1.176 mg. This provides a dose reference for clinical application.
HUANG Guangyong
,
HUANG Minzhen
,
LIU Baoyun
. A dose-response relationship study of oliceridine combined with propofol for gastrointestinal endoscopy[J]. Surgical Research and New Technique, 2025
, 14(3)
: 230
-233
.
DOI: 10.3969/j.issn.2095-378X.2025.03.007
[1] Hu J, Wang X, Sun S.Comparison between the widely used magnetically controlled capsule gastroscopy and conventional gastroscopy: a meta-analysis[J]. Minim Invasive Ther Allied Technol,2022,31(4):496-504.
[2] 蔡璋曦. 苯磺酸瑞马唑仑麻醉对老年无痛胃肠镜检查患者血流动力学的影响[J]. 外科研究与新技术(中英文),2024,13(2):146-149.
[3] Pardo E, Camus M, Verdonk F.Anesthesia for digestive tract endoscopy[J]. Curr Opin Anaesthesiol,2022,35(4):528-535.
[4] De Boer HD, Detriche O, Forget P.Opioid-related side effects:postoperative ileus,urinary retention,nausea and vomiting,and shivering.A review of the literature[J]. Best Pract Res Clin Anaesthesiol,2017,31(4):499-504.
[5] Zhou S, Zhu Z, Dai W, et al.National survey on sedation for gastrointestinal endoscopy in 2758 Chinese hospitals[J]. Br J Anaesth,2021,127(1):56-64.
[6] 冯艺,许军军,中华医学会麻醉学分会中国全凭静脉麻醉临床实践指南(2024版)编写组. 中国全凭静脉麻醉临床实践指南(2024版)[J]. 中华麻醉学杂志,2024,44(9):1030-1049.
[7] 李慎占,董河. 地佐辛的临床应用研究[J]. 医学综述,2012,18(23):4021-4023.
[8] 徐佳明,周晓芳,郭建荣. 不同阿片受体激动拮抗剂联合丙泊酚用于人工流产手术的镇痛效果比较[J]. 妇儿健康导刊,2023,2(1):15-18,31.
[9] 朱昌茂,谢力,吴仔峰,等. 偏向性μ-阿片受体激动剂奥赛利定的临床应用进展[J]. 中国临床药理学与治疗学,2024,29(9):1057-1061.
[10] 苏娅萍. 奥赛利定的作用机制、药理作用以及临床应用[J]. 中国药物滥用防治杂志,2024,30(4):583-586.
[11] 陈功,欧阳文,戴茹萍,等. 奥赛利定治疗全麻患者术后中重度疼痛的有效性和安全性:随机、盲法、阳性对照、多中心临床试验[J]. 中华麻醉学杂志,2024,44(2):135-139.
[12] 邢文鑫,张宗旺. 新型阿片类药物奥赛利定[J]. 国际麻醉学与复苏杂志,2023,44(10):1116-1120.
[13] 樊永正,韩丽君,赵亮. 呼吸抑制作用减弱的新型阿片类药物研究进展[J]. 中国新药与临床杂志,2024,43(5):327-333.
[14] Sidhu R, Turnbull D, Haboubi H, et al.British Society of Gastroenterology guidelines on sedation in gastrointestinal endoscopy[J]. Gut,2024,73(2):1-27.
[15] Yang H, Zhao Q, Chen H, et al.The median effective concentration of propofol with different doses of esketamine during gastrointestinal endoscopy in elderly patients:a randomized controlled trial[J]. Br J Clin Pharmacol,2022,88(3):1279-1287.
[16] Markham A.Oliceridine:first approval[J]. Drugs,2020,80(16):1739-1744.
[17] 孙雪梅,汤黎黎,钟薇薇,等. 无痛消化内镜诊疗中镇静镇痛药物应用的研究进展[J]. 淮海医药,2022,40(2):209-212.
[18] Hu Y, Xu W, Cao F.A meta-analysis of randomized controlled trials:combination of ketamine and propofol versus ketamine alone for procedural sedation and analgesia in children[J]. Intern Emerg Med,2019,14(7):1159-1165.
[19] Xiao X, Xiao N, Zeng F, et al.Gastroscopy sedation:clinical trial comparing propofol and sufentanil with or without remimazolam[J]. Minerva Anestesiol,2022,88(4):223-229.
[20] Bateman JT, Saunders SE, Levitt ES.Understanding and countering opioid‐induced respiratory depression[J]. Br J Pharmacol,2023,180(7):813-828.
[21] Mann J, Samieegohar M, Chaturbedi A, et al.Development of a translational model to assess the impact of opioid overdose and naloxone dosing on respiratory depression and cardiac arrest[J]. Clin Pharmacol Ther,2022,112(5):1020-1032.
[22] Dahan A, van Dam CJ, Niesters M, et al. Benefit and risk evaluation of biased μ-receptor agonist oliceridine versus morphine[J]. Anesthesiology,2020,133(3):559-568.
[23] Ok HG, Kim SY, Lee SJ, et al.Can oliceridine (TRV130),an ideal novel µ receptor G protein pathway selective (µ-GPS) modulator,provide analgesia without opioid-related adverse reactions?[J]. Korean J Pain,2018,31(2):73-79.
[24] Nafziger AN, Arscott KA, Cochrane K, et al.The influence of renal or hepatic impairment on the pharmacokinetics,safety,and tolerability of oliceridine[J]. Clin Pharmacol Drug Dev,2020,9(5):639-650.
